Mental disorders represent a worldwide public health concern. Psychotherapies and
pharmacotherapies are recommended as first line treatments. However, evidence has …

Major depressive disorder is a common psychiatric disorder associated with marked
suffering, morbidity, mortality, and cost. The World Health Organization projects that by 2030 …

The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published
treatment guidelines for bipolar disorder in 2005, along with international commentaries and …

Individuals with substance use disorders (SUDs) are at increased risk for COVID‐19
infection and for adverse outcomes of the infection. Though vaccines are highly effective …

We summarize evidence supporting contemporary pharmacological treatment of phases of
BD, including: mania, depression, and long-term recurrences, emphasizing findings from …

Lithium (Li+) is a first option treatment for adult acute episodes of Bipolar Disorder (BD) and
for the prophylaxis of new depressed or manic episodes. It is also the preferred choice as …

Bipolar disorders, including bipolar I disorder (BP-I) and bipolar II disorder (BP-II), are
common, potentially disabling, and, in some cases, life-threatening conditions. Bipolar …

Over the last six decades, lithium has been considered the gold standard treatment for the
long-term management of bipolar disorder due to its efficacy in preventing both manic and …

Cognitive deficits are a core feature of serious mental illnesses such as schizophrenia,
major depressive disorder (MDD) and bipolar disorder (BD) and are a common cause of …

Bipolar disorder (BD) is a major health problem. It causes significant morbidity and imposes
a burden on the society. Available treatments help a substantial proportion of patients but …